In this context, nanoparticles that specifically bind to particular T-cell subsets have been designed (Schmid et al., 2017), and inhibiting autophagy in CD4+ and CD8+ autoreactive T-cells could prevent the initial activation of the immune response seen in MS. Here, CD4 is linked to myeloid sarcoma.